Latest News

  • Egg metabolites in blood related to lower risk of type 2 diabetes
    Consumption of one egg every day seems to associate with a blood metabolite profile that is related to a lower risk of type 2 diabetes, a new study conducted in the University of Eastern Finland shows. The findings were published in Molecular Nutrition and Food Research.
  • Belgian beer landscape mapped using scientific insights
    A unique scientific analysis and comparison of 250 Belgian beers in a new book aimed at beer geeks as well as novices - ‘Belgian beer, tested and tasted’
  • Is Mesoblast’s acute Graft versus Host Disease product poised to fulfil the promise of mesenchymal stem cells?
    The therapeutic use of mesenchymal stem cells or MSCs was first investigated in humans in 1995, generating a great deal of early enthusiasm about their promise as easily manufactured allogeneic cellular medicines. Since 1995, MSCs have become one of the most clinically studied experimental cell therapy platforms in the world. After more than 20 years of MSC clinical research, which has not yet resulted in an FDA-approved therapy, many people have questioned whether they can fulfil their therapeutic promise.
  • Cancer Research UK Tests First Of Its Kind Vaccine To Treat Lung Cancer
    A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc.
  • First patient treated in Follicum’s Phase IIa study of FOL-005 for stimulation of hair growth
    Follicum AB have announced that the firstpatient has been treated in the Phase IIa clinical trial in Germany with its lead candidate FOL-005 on 60 patients with hair loss. The study is conducted at Clinical Research Center for Hair and Skin Science (“CRC”) in Berlin and bioskin, Hamburg, Germany. The global market for pharmaceutical hair lossproducts for both men and women is estimated to be worth $3 billion. The available drug products have unwanted side-effects that limit their use.
view more


view more


  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more


  • Securing reliability and validity in biomedical research: an essential task
    This article discusses the impact of ‘old’ and contemporary data on hypothesis generation in relation to human physiology and in the effort to optimally implement translational sciences.
  • Translational research the changing landscape of drug discovery
    In this article the author discusses how the increasing adoption of translational research is leading to novel integrated discovery nexuses that may change the landscape of drug discovery.
  • Translational medicines research
    This article discusses fundamental processes of translational research: Understanding the biological basis of human disorders; Lead generation and optimisation; Clinical testing
  • Translational CNS medicines research
    Translating neuroscience research into new medicines is challenging, largely because of the complexity of the human brain. The critical factors involved in this process are considered, along with the future prospects.
  • Decision support methods for the detection of adverse events
    Spontaneous reporting is a crucial component of post-marketing drug safety surveillance despite its significant limitations. The size and complexity of some spontaneous reporting system databases represent a challenge for drug safety professionals who traditionally have relied heavily on the scientific and clinical acumen of the prepared mind. Computer algorithms that calculate statistical measures of reporting frequency for huge numbers of drug-event combinations are increasingly used to support pharamcovigilance analysts screening large spontaneous reporting system databases.
view more

25 Hottest Articles

view more